ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Unum Therapeutics Inc

Unum Therapeutics Inc (UMRX)

2.35
0.00
(0.00%)
Closed November 23 4:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.35
Bid
2.35
Ask
2.40
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
2.35
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
86,124,000
Dividend Yield
-
PE Ratio
-1.05
Earnings Per Share (EPS)
-2.23
Revenue
-
Net Profit
-192.41M

About Unum Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
-

UMRX Latest News

Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.Β (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...

Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress

Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision...

SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics

SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, MassachusettsUnum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all...

Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO

Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO Transaction focused on the BOXR technology including lead program BOXR1030 Company fully focused on the development of...

Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates Completed acquisition of Kiq, including lead clinical-stage compound PLX9486, a potent and selective...

Unum Therapeutics Inc. Announces Acquisition of Kiq LLC

Unum Therapeutics Inc. Announces Acquisition of Kiq LLC Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor Company positioned to advance...

Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today...

Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates

CAMBRIDGE, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today...

Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today...

Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cance...

BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PDYNPalladyne AI Corporation
$ 4.59
(129.50%)
83M
QMCOQuantum Corporation
$ 9.11
(126.62%)
39.41M
NANano Labs Ltd
$ 8.26
(89.02%)
2.03M
XCURExicure Inc
$ 18.60
(71.27%)
4.36M
SKKSKK Holdings Limited
$ 1.75
(59.09%)
95.06M
AMIXAutonomix Medical Inc
$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
$ 8.24
(18.05%)
107.91M

UMRX Discussion

View Posts
TFMG TFMG 4 years ago


$UMRX | #UNUM Therapeutics Potential 25% Upside


Nice rally has taken hold post earnings .
Alert is set for break above $3.50
Indicators are in bullish reversal and room to run much higher
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.



πŸ‘οΈ0
byrdiesoccer byrdiesoccer 4 years ago
Do not*
πŸ‘οΈ0
byrdiesoccer byrdiesoccer 4 years ago
Do waste your time with that poster. Venrock knows what the F they are doing. This will be a $10 stock before you know it at least
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
Tell that to all the new major fund holders. Read all the 13g's and form 3's recently and look at the tiny float and OS. No brainer UMRX has been a hold for quite awhile now. The chart has been perfect. It is great for longs and swing traders have had some great swings also.
πŸ‘οΈ0
surf1944 surf1944 4 years ago
Now you may ride it all the way back down!
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
ROTFLMAO we already rode it up to almost $5.00 from .50. GL with that!
πŸ‘οΈ0
surf1944 surf1944 4 years ago
https://www.stockscores.com/charts/charts/?ticker=UMRX

Open gap on the chart @ .50
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
I agree and based on the chart and recent huge run we should see UMRX over $5.00 soon.
This one will run very soon. Venrock doesn’t play....
πŸ‘οΈ0
byrdiesoccer byrdiesoccer 4 years ago
This one will run very soon. Venrock doesn’t play....
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
It was news a few days ago. This bard is not active. Anyone who wanted to sell could have. These are frivolous lawsuits on stocks that run hard. I ignore them they happen on almost all recent hot big board stocks. Just more desperate lawyers. Focus on the real news the 104 million dollar buyout merger that just happened. And all the 13g's. Those are very large investment groups loading up huge on UMRX.
πŸ‘οΈ0
aljafy aljafy 4 years ago
Why has this not been mentioned?:

https://finance.yahoo.com/news/kaskela-law-llc-announces-investigation-123000510.html

Kaskela Law LLC Announces Investigation of Unum Therapeutics Inc. and Encourages Long-Term Investors to Contact the Firm - UMRX
PR Newswire PR Newswireβ€’July 21, 2020
PHILADELPHIA, July 21, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Unum Therapeutics Inc. (NASDAQ: UMRX) ("Unum" or the "Company") on behalf of the Company's investors.

The investigation seeks to determine whether Unum and/or the Company's officers and directors have violated the securities laws in connection with recent corporate actions, and whether Unum investors have been harmed as a result.

Unum investors are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email at skaskela@kaskelalaw.com or online at http://kaskelalaw.com/case/unum-therapeutics-inc/, for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

CONTACT:

D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
(888) 715 – 1740
skaskela@kaskelalaw.com
www.kaskelalaw.com
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
I agree. Read all the 13g's lately. Big money has been loading UMRX. Any day now we should run huge above easily over $4.00 to $5.00 IMO. VENROCK takes 5% stake was the last 13g this week.
Follow Venrock money when you can. They loaded heavy in Humanigen as well
πŸ‘οΈ0
byrdiesoccer byrdiesoccer 4 years ago
Follow Venrock money when you can. They loaded heavy in Humanigen as well
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
$UMRX VENROCK takes 5% stake another big 13 g filed today
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
UMRX another 13g afterhours today. Could move up big green tomorrow like we did on Friday. The charts so on a $3.50 break we should head to $5.00.
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
UMRX 104 million dollars on the recent buyout, low SS and float ready for the next leg up IMO over $5.00 and more. We got more filings on this yesterday time to run hard on HUGE volume again refer tot he charts.
Sweet explosion UMRX on news https://finance.yahoo.com/news/unum-therapeutics-inc-announces-acquisition-141600836.html
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
UMRX moved afterhours I see because of more filings. We got 13g filings. Time to set up the next big run ahead..
πŸ‘οΈ0
PickleNick PickleNick 4 years ago
Right! Amazing play here. Raised over $100M and purchased a therapeutic company in KIQ. Easy play here
πŸ‘οΈ0
cjstocksup cjstocksup 4 years ago
UMRX! I agree! $5.00 Monday for UMRX? Shorts have been getting killed daily here, I love it! Pre market this AM at about $4.50 was fun.
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $UMRX Video Chart 07-10-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
PickleNick PickleNick 4 years ago
MONSTER!!!!!
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $UMRX Video Chart 07-07-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
wesley_ wesley_ 4 years ago
$3.08 :D
πŸ‘οΈ0
PickleNick PickleNick 4 years ago
Beautiful
πŸ‘οΈ0
wesley_ wesley_ 4 years ago
hod $2.69 what a monster
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $UMRX Video Chart 07-06-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
$treet $inatra $treet $inatra 4 years ago
Sweet explosion UMRX on news https://finance.yahoo.com/news/unum-therapeutics-inc-announces-acquisition-141600836.html
πŸ‘οΈ0
trendzone trendzone 4 years ago
Today's shorties throw in the pot for lunch, their going to make good chicken soup when fully boiled.
πŸ‘οΈ0
wesley_ wesley_ 4 years ago
$2.18 nice runner
πŸ‘οΈ0
wesley_ wesley_ 4 years ago
$1.83 sweet
πŸ‘οΈ0
wesley_ wesley_ 4 years ago
$1.73 lovely
πŸ‘οΈ0
wesley_ wesley_ 4 years ago
$1.42 nice
πŸ‘οΈ0
swanlinbar swanlinbar 4 years ago
UMRX they voted on Monday,Anyone know if they are going forward with R/S ? Thanks
πŸ‘οΈ0
swanlinbar swanlinbar 4 years ago
UMRX out for now
πŸ‘οΈ0
swanlinbar swanlinbar 4 years ago
UMRX-Unum Therapeutics $UMRX Raised to Buy at Zacks Investment Research
πŸ‘οΈ0
swanlinbar swanlinbar 4 years ago
UMRX Patience
πŸ‘οΈ0
swanlinbar swanlinbar 4 years ago
UMRX-Unum Therapeutics Inc (NASDAQ:UMRX) Receives Consensus Recommendation of β€œBuy” from Analysts
Posted by ABMN Staff on May 28th, 2020 // No Comments

Unum Therapeutics logoUnum Therapeutics Inc (NASDAQ:UMRX) has earned an average recommendation of β€œBuy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $2.88.

Several equities research analysts have recently weighed in on the stock. Morgan Stanley downgraded shares of Unum Therapeutics from an β€œoverweight” rating to an β€œequal weight” rating in a research report on Tuesday, March 3rd. Zacks Investment Research raised shares of Unum Therapeutics from a β€œhold” rating to a β€œbuy” rating and set a $0.50 target price for the company in a research report on Friday, March 6th. Wedbush reissued a β€œhold” rating and issued a $1.00 target price on shares of Unum Therapeutics in a research report on Sunday, March 29th. Finally, HC Wainwright dropped their target price on shares of Unum Therapeutics from $18.00 to $4.00 and set a β€œbuy” rating for the company in a research report on Friday, March 27th.
πŸ‘οΈ0
swanlinbar swanlinbar 4 years ago
UMRX has been Churning here for awhile
πŸ‘οΈ0
swanlinbar swanlinbar 4 years ago
πŸ‘οΈ0
BluSkies BluSkies 5 years ago
On watch
πŸ‘οΈ0
swanlinbar swanlinbar 5 years ago
UMRX chewing away,little by little imo
πŸ‘οΈ0
swanlinbar swanlinbar 5 years ago
UMRX yes waiting on an Update
πŸ‘οΈ0
swanlinbar swanlinbar 5 years ago
UMRX need to get by that nut @.58
πŸ‘οΈ0
Hole shot King Hole shot King 5 years ago
$UMRX is coming
πŸ‘οΈ0
swanlinbar swanlinbar 5 years ago
UMRX could be today
πŸ‘οΈ0
Hole shot King Hole shot King 5 years ago
$UMRX twitter

https://twitter.com/unumrx/
πŸ‘οΈ0
swanlinbar swanlinbar 5 years ago
UMRX latest Presentation March 2020 https://investors.unumrx.com/static-files/1f2dcf12-9740-4372-8bd3-40a6127a7531
πŸ‘οΈ0
swanlinbar swanlinbar 5 years ago
UMRX
https://unumrx.com/
πŸ‘οΈ0
Hole shot King Hole shot King 5 years ago
Unum Therapeutics In $UMRX
0.5401 up 0.0403 (8.06%)
Volume: 1,123,922

πŸ‘οΈ0
swanlinbar swanlinbar 5 years ago
UMRX Note the level of insider ownership (35%) and recent insider transactions. Note the lack of fluff press releases.)
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock